{"id":"zidovudine-lamivudine-efavirenz","safety":{"commonSideEffects":[{"rate":"40-50","effect":"Dizziness and CNS effects"},{"rate":"15-25","effect":"Nausea"},{"rate":"10-20","effect":"Rash"},{"rate":"10-15","effect":"Headache"},{"rate":"null","effect":"Lipodystrophy"},{"rate":"null","effect":"Lactic acidosis"},{"rate":"null","effect":"Hepatotoxicity"}]},"_chembl":{"chemblId":"CHEMBL223228","moleculeType":"Small molecule","molecularWeight":"315.68"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Zidovudine and lamivudine are nucleoside reverse transcriptase inhibitors (NRTIs) that compete with natural nucleotides to terminate viral DNA chain elongation. Efavirenz is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that directly binds and inhibits reverse transcriptase. Together, this triple-drug regimen suppresses HIV viral load by targeting multiple steps of viral replication.","oneSentence":"This combination of three antiretroviral drugs inhibits HIV replication by blocking reverse transcriptase and integrase enzymes, preventing the virus from copying its genetic material and integrating into host cells.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:16:32.506Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"HIV-1 infection in treatment-naïve and treatment-experienced patients"}]},"trialDetails":[{"nctId":"NCT02016924","phase":"PHASE2, PHASE3","title":"Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIV","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gilead Sciences","startDate":"2014-01-16","conditions":"Acquired Immune Deficiency Syndrome (AIDS), HIV Infections","enrollment":133},{"nctId":"NCT06337032","phase":"PHASE4","title":"A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Clinical Studies Involving Gilead HIV Treatments","status":"RECRUITING","sponsor":"Gilead Sciences","startDate":"2024-08-27","conditions":"HIV-1-infection","enrollment":350},{"nctId":"NCT05502341","phase":"PHASE2, PHASE3","title":"Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With a Complicated Regimen","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gilead Sciences","startDate":"2022-08-16","conditions":"HIV-1-infection","enrollment":689},{"nctId":"NCT07080138","phase":"","title":"Research on the Psychological Status of Patients With HIV-1 Infection","status":"NOT_YET_RECRUITING","sponsor":"Shanxi Bethune Hospital","startDate":"2025-08-01","conditions":"HIV-1-infection, Anxiety Depression","enrollment":500},{"nctId":"NCT00476606","phase":"","title":"A Prospective Cohort of Children With HIV Infection","status":"COMPLETED","sponsor":"The HIV Netherlands Australia Thailand Research Collaboration","startDate":"2003-03","conditions":"HIV Infections","enrollment":500},{"nctId":"NCT03178084","phase":"PHASE3","title":"Effects of Maraviroc vs. Efavirenz on CD4/CD8 Ratio","status":"COMPLETED","sponsor":"Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal","startDate":"2014-10-15","conditions":"HIV/AIDS","enrollment":721},{"nctId":"NCT05525156","phase":"PHASE2","title":"The Effect of Aspirin on HIV Disease Progression Among HIV- Infected Individuals Initiating Anti- Retroviral Therapy","status":"SUSPENDED","sponsor":"Muhimbili University of Health and Allied Sciences","startDate":"2020-03-02","conditions":"Hiv, Cardiovascular Diseases","enrollment":454},{"nctId":"NCT00074581","phase":"PHASE3","title":"Preventing Sexual Transmission of HIV With Anti-HIV Drugs","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2005-02","conditions":"HIV Infections","enrollment":3526},{"nctId":"NCT00039741","phase":"PHASE2, PHASE3","title":"Anti-HIV Drug Regimens and Treatment-Switching Guidelines in HIV Infected Children","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2002-08","conditions":"HIV Infections","enrollment":266},{"nctId":"NCT00102960","phase":"PHASE3","title":"Anti-HIV Drugs for Treating Infants Who Acquired HIV Infection at Birth","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2005-07","conditions":"HIV Infections","enrollment":377},{"nctId":"NCT00001087","phase":"PHASE2","title":"The Effectiveness of Nelfinavir and Efavirenz, Used Alone or Together, Combined With Other Anti-HIV Drugs in Patients Who Have Taken Anti-HIV Drugs","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":300},{"nctId":"NCT00050895","phase":"PHASE3","title":"Comparing the Safety, Effectiveness, and Tolerability of Three Anti-HIV Drug Regimens for Treatment-Naive Patients","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":775},{"nctId":"NCT00000885","phase":"PHASE2","title":"Treatment Success and Failure in HIV-Infected Subjects Receiving Indinavir in Combination With Nucleoside Analogs: A Rollover Study for ACTG 320","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":440},{"nctId":"NCT03631732","phase":"PHASE3","title":"Study to Evaluate Switching From a Regimen of Two Nucleos(t)Ide Reverse Transcriptase Inhibitors (NRTI) Plus a Third Agent to a Fixed Dose Combination (FDC) of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF), in Virologically-Suppressed, HIV-1 Infected African American Participants","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2018-08-28","conditions":"HIV-1 Infection","enrollment":496},{"nctId":"NCT02057796","phase":"PHASE4","title":"Systematic Empirical vs. Test-guided Anti-TB Treatment Impact in Severely Immunosuppressed HIV-infected Adults Initiating ART With CD4 Cell Counts <100/mm3","status":"COMPLETED","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2014-09","conditions":"HIV-1 Infection","enrollment":1050},{"nctId":"NCT03284645","phase":"","title":"Viral and Antiretroviral Dynamics in HIV-1 Mother-to-Child Transmission Fluids","status":"COMPLETED","sponsor":"Obafemi Awolowo University","startDate":"2017-12-22","conditions":"Human Immunodeficiency Virus Infection","enrollment":194},{"nctId":"NCT01075152","phase":"PHASE4","title":"Cryptococcal Optimal ART Timing Trial","status":"COMPLETED","sponsor":"University of Minnesota","startDate":"2010-11","conditions":"Cryptococcal Meningitis, HIV Infections, AIDS","enrollment":177},{"nctId":"NCT01618305","phase":"PHASE4","title":"Evaluating the Response to Two Antiretroviral Medication Regimens in HIV-Infected Pregnant Women, Who Begin Antiretroviral Therapy Between 20 and 36 Weeks of Pregnancy, for the Prevention of Mother-to-Child Transmission","status":"COMPLETED","sponsor":"Westat","startDate":"2013-09-05","conditions":"HIV Infections","enrollment":408},{"nctId":"NCT00993031","phase":"PHASE3","title":"Protease Inhibitors to Reduce Malaria Morbidity in HIV-Infected Pregnant Women","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2009-12-15","conditions":"Malaria, HIV Infections","enrollment":389},{"nctId":"NCT00978068","phase":"PHASE3","title":"HIV Protease Inhibitors for the Prevention of Malaria in Ugandan Children","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2009-09","conditions":"Malaria, HIV Infections","enrollment":176},{"nctId":"NCT00084136","phase":"PHASE4","title":"Prospective Evaluation of Anti-retroviral Combinations for Treatment Naive, HIV Infected Persons in Resource-limited Settings","status":"COMPLETED","sponsor":"Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections","startDate":"2005-05","conditions":"HIV Infections","enrollment":1571},{"nctId":"NCT00427297","phase":"PHASE3","title":"Optimizing Pediatric HIV-1 Treatment in Infants With Prophylactic Exposure to Nevirapine, Nairobi, Kenya","status":"TERMINATED","sponsor":"University of Washington","startDate":"2007-09","conditions":"HIV Infections","enrollment":34},{"nctId":"NCT01714414","phase":"PHASE2","title":"A Trial to Confirm a Sustained Virological Suppression Defined as HIV-RNA <50 Copies/ml of 3 Different Doses of Fozivudine in Context to a Standard Zidovudine Based Antiretroviral Therapy Regimen","status":"COMPLETED","sponsor":"Michael Hoelscher","startDate":"2012-12","conditions":"HIV-1 Infection","enrollment":120},{"nctId":"NCT02499874","phase":"PHASE1","title":"SSAT063- Pharmacokinetics of Efavirenz 400 mg Once Daily During Pregnancy in HIV-1 Infected Women","status":"COMPLETED","sponsor":"St Stephens Aids Trust","startDate":"2015-08","conditions":"HIV","enrollment":26},{"nctId":"NCT01516970","phase":"PHASE3","title":"Human Immunodeficiency Virus (HIV) Postexposure Prophylaxis (PEP) With Darunavir/Ritonavir (DRV/r)","status":"COMPLETED","sponsor":"Janssen-Cilag G.m.b.H","startDate":"2011-11-25","conditions":"Human Immunodeficiency Virus (HIV)","enrollment":312},{"nctId":"NCT02832778","phase":"PHASE1","title":"Pharmacokinetics of Efavirenz in the Presence of Rifampicin and Isoniazid","status":"UNKNOWN","sponsor":"St Stephens Aids Trust","startDate":"2016-11-21","conditions":"HIV","enrollment":35},{"nctId":"NCT01387022","phase":"NA","title":"Trial to Assess the Impact of PrEP to Tenofovir Gel on the Efficacy of Tenofovir-containing ART on Viral Suppression","status":"COMPLETED","sponsor":"Centre for the AIDS Programme of Research in South Africa","startDate":"2011-06","conditions":"Antiretroviral Treatment Outcomes","enrollment":59},{"nctId":"NCT01340950","phase":"PHASE4","title":"Clinical Trial of Brain-Penetrating HIV Drugs to Prevent Cognitive Impairment in China","status":"COMPLETED","sponsor":"University of California, San Diego","startDate":"2010-07","conditions":"HIV Infections, Central Nervous System Diseases, Dementia","enrollment":250},{"nctId":"NCT01908660","phase":"","title":"Hepatic Safety of Currently Used Antiretroviral Regimens in Patients With Chronic Hepatitis Under Real Life Conditions","status":"COMPLETED","sponsor":"Valme University Hospital","startDate":"2007-01","conditions":"Human Immunodeficiency Virus, Hepatitis B, Chronic, Hepatitis C, Chronic","enrollment":192},{"nctId":"NCT01192035","phase":"PHASE4","title":"PI or NNRTI as First-line Treatment of HIV in West Africa - the PIONA Trial","status":"COMPLETED","sponsor":"University of Aarhus","startDate":"2011-05","conditions":"HIV-1","enrollment":400},{"nctId":"NCT00192595","phase":"PHASE4","title":"Tenofovir in HIV/HBV Coinfection","status":"COMPLETED","sponsor":"Kirby Institute","startDate":"2004-01","conditions":"HIV Infection, Hepatitis B Coinfection","enrollment":36},{"nctId":"NCT01583439","phase":"NA","title":"The Mochudi Prevention Project ART Protocol","status":"TERMINATED","sponsor":"Harvard School of Public Health (HSPH)","startDate":"2012-09","conditions":"HIV Infections","enrollment":11},{"nctId":"NCT00031070","phase":"PHASE2","title":"Increasing HAART-Induced Immune Restoration With Cyclosporine","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":40},{"nctId":"NCT01694017","phase":"PHASE4","title":"Economic, Clinical and Quality of Life Assessment in Patients on Antiretroviral Therapy","status":"COMPLETED","sponsor":"Tufts University","startDate":"2012-11","conditions":"HIV","enrollment":68},{"nctId":"NCT00120510","phase":"NA","title":"Early Versus Standard Start of Anti-HIV Therapy for Treatment-Naive Adults in Haiti","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2007-07","conditions":"HIV Infections, Tuberculosis","enrollment":816},{"nctId":"NCT01565889","phase":"PHASE1, PHASE2","title":"Part A: Drug Interaction Study of Sofosbuvir and Antiretroviral Therapy (ART) Combinations in HIV and Hepatitis C Virus (HCV) Co-infected Patients. Part B: Efficacy and Safety of Sofosbuvir for 12 Weeks in HIV/HCV Co-infected Patients.","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2012-03","conditions":"Hepatitis C, HIV","enrollment":52},{"nctId":"NCT00110305","phase":"PHASE2","title":"A Study of TMC278 in Human Immunodeficiency Virus Type 1 Infected Patients, Who Are Not Treated With Antiretroviral Medicines","status":"COMPLETED","sponsor":"Tibotec Pharmaceuticals, Ireland","startDate":"2005-06","conditions":"Human Immunodeficiency Virus Type 1","enrollment":368},{"nctId":"NCT02028676","phase":"PHASE4","title":"Efficacy Study of Different Laboratory Management Strategies and Drug Regimens in HIV-infected Children in Africa","status":"COMPLETED","sponsor":"Medical Research Council","startDate":"2007-03","conditions":"Human Immunodeficiency Virus","enrollment":1206},{"nctId":"NCT00624195","phase":"PHASE2, PHASE3","title":"Clinical Trial of CNS-targeted HAART (CIT2)","status":"COMPLETED","sponsor":"University of California, San Diego","startDate":"2007-03","conditions":"HIV Infections","enrollment":59},{"nctId":"NCT02002286","phase":"NA","title":"Safety and Efficacy Study of TwHF in HIV Patients With Poor Immune Responses","status":"COMPLETED","sponsor":"LI Taisheng","startDate":"2011-08","conditions":"HIV","enrollment":23},{"nctId":"NCT00234091","phase":"PHASE3","title":"When to Start Anti-HIV Drugs in Children Infected With HIV (The PREDICT Study)","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2006-04","conditions":"HIV Infections","enrollment":300},{"nctId":"NCT00098293","phase":"PHASE3","title":"Trial of Maraviroc (UK-427,857) in Combination With Zidovudine/Lamivudine Versus Efavirenz in Combination With Zidovudine/Lamivudine","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2004-11","conditions":"HIV-1","enrollment":916},{"nctId":"NCT00100568","phase":"NA","title":"Efavirenz and Lamivudine/Zidovudine for Treatment-Naive HIV Infected Adults in Senegal","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2006-07","conditions":"HIV Infections","enrollment":44},{"nctId":"NCT00050908","phase":"","title":"Blood Vessel Function in HIV-Infected Patients Taking Anti-HIV Drugs","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":75},{"nctId":"NCT00014937","phase":"NA","title":"Simplified Drug Regimens for HIV Patients in ACTG 388 or Patients Who Responded to A First Potent Combination Regimen","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":240},{"nctId":"NCT00342355","phase":"PHASE4","title":"Antiretroviral Therapy for Advanced HIV Disease in South Africa","status":"COMPLETED","sponsor":"National Institutes of Health Clinical Center (CC)","startDate":"2004-01","conditions":"HIV","enrollment":1771},{"nctId":"NCT01817283","phase":"PHASE1, PHASE2","title":"Impact on T Cell Immune Activation and Inflammation of Triptolide Woldifii in HIV-infected Immunological Non-responders","status":"UNKNOWN","sponsor":"LI Taisheng","startDate":"2013-01","conditions":"HIV","enrollment":150},{"nctId":"NCT00666055","phase":"","title":"Sex, Aging and Antiretroviral Pharmacokinetics","status":"COMPLETED","sponsor":"Kristine Patterson, MD","startDate":"2008-03","conditions":"HIV Infections","enrollment":11},{"nctId":"NCT00197613","phase":"PHASE3","title":"The Adult Antiretroviral Treatment and Resistance Study (Tshepo)","status":"COMPLETED","sponsor":"Harvard School of Public Health (HSPH)","startDate":"2002-12","conditions":"AIDS, HIV Infection","enrollment":650},{"nctId":"NCT00000919","phase":"NA","title":"A Study to Evaluate Various Combinations of Anti-HIV Medications to Treat Early HIV Infection","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":900},{"nctId":"NCT00000903","phase":"PHASE3","title":"Addition of Efavirenz or Nelfinavir to a Lamivudine/Zidovudine/Indinavir HIV Treatment Regimen","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":444},{"nctId":"NCT00000918","phase":"PHASE2","title":"A Study to Compare The Ability of Different Anti-HIV Drugs to Decrease Viral Load After Nelfinavir (an Anti-HIV Drug)Treatment Failure","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":300},{"nctId":"NCT00013520","phase":"PHASE3","title":"Comparison of Three Different Initial Treatments Without Protease Inhibitors for HIV Infection","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":1125},{"nctId":"NCT00192660","phase":"PHASE4","title":"HIV Infection And Metabolic Abnormalities Protocol 1 (HAMA001)","status":"COMPLETED","sponsor":"Kirby Institute","startDate":"2003-02","conditions":"HIV-Associated Lipodystrophy Syndrome, Cardiovascular Disease","enrollment":80},{"nctId":"NCT00936195","phase":"PHASE3","title":"Universal Use of EFV-TDF-FTC and AZT-3TC-LPV/r Combinations for HIV-1 PMTCT in Pregnant and Breastfeeding Women : a Phase 3 Trial","status":"WITHDRAWN","sponsor":"French National Agency for Research on AIDS and Viral Hepatitis","startDate":"2010-01","conditions":"HIV Infection, Pregnancy, Breastfeeding","enrollment":""},{"nctId":"NCT00013897","phase":"PHASE3","title":"A Comparison of BMS-232632 With Efavirenz, Each in Combination With Zidovudine-Lamivudine","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2001-02","conditions":"HIV Infections","enrollment":""},{"nctId":"NCT00001119","phase":"NA","title":"Effects on the Immune System of Anti-HIV Drugs in Patients Recently Infected With HIV","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"1999-10","conditions":"HIV Infections","enrollment":288},{"nctId":"NCT00028327","phase":"PHASE3","title":"Potent Antiviral Therapy for Critically Ill HIV Infected Patients Admitted to Intensive Care","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":250},{"nctId":"NCT00021463","phase":"PHASE2","title":"Changing to Nonprotease Inhibitor Treatment to Improve Side Effects","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections, Lipodystrophy","enrollment":342},{"nctId":"NCT00100594","phase":"NA","title":"Efavirenz and Lamivudine/Zidovudine for Treatment-Naive HIV Infected People in Wenxi County, Shanxi Province, China","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2005-05","conditions":"HIV Infections","enrollment":100},{"nctId":"NCT01273142","phase":"","title":"Compare to the Safety of Efavirenz and Nevirapine in Treating HIV Positive Patients With Mild Baseline Liver Function Test Impairment, and/or Hepatitis B or Hepatitis C Co-infection","status":"UNKNOWN","sponsor":"Henan Provincial People's Hospital","startDate":"2011-01","conditions":"HIV Infections, Liver Toxicity, Hepatitis Co-infection","enrollment":100},{"nctId":"NCT00112047","phase":"PHASE3","title":"Tenofovir Disoproxil Fumarate/Emtricitabine/Efavirenz Versus Combivir/Efavirenz in Antiretroviral-Naive HIV-1 Infected Subjects","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2003-07","conditions":"HIV Infections","enrollment":517},{"nctId":"NCT00966160","phase":"PHASE3","title":"CD4 Cell Recovery in HIV-1 Patients Comparing 2 Treatment Regimes","status":"COMPLETED","sponsor":"University of Cologne","startDate":"1999-01","conditions":"Acquired Immunodeficiency Syndrome, HIV Infections","enrollment":215},{"nctId":"NCT00158405","phase":"PHASE3","title":"Randomised Trial of Structured Treatment Interruption of HAART in HIV-Infected Adults in Abidjan (ANRS 1269 TRIVACAN)","status":"COMPLETED","sponsor":"French National Agency for Research on AIDS and Viral Hepatitis","startDate":"2002-12","conditions":"HIV Infections","enrollment":840},{"nctId":"NCT00433719","phase":"NA","title":"Immediate Versus Deferred Antiretroviral Therapy for HIV-Associated Tuberculous Meningitis","status":"UNKNOWN","sponsor":"University of Oxford","startDate":"2005-09","conditions":"HIV Infections, Tuberculous Meningitis","enrollment":253},{"nctId":"NCT00323544","phase":"PHASE3","title":"SWEET: Once Daily Truvada Versus Twice Daily Combivir for the Treatment of HIV Infection","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2004-10","conditions":"HIV Infections","enrollment":220},{"nctId":"NCT00224458","phase":"PHASE4","title":"Combination of Efavirenz and Truvada - COMET Study","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2004-09","conditions":"HIV Infections","enrollment":400},{"nctId":"NCT00256828","phase":"PHASE4","title":"Once a Day (QD) - Twice a Day (BID) Clinical Trial: Didanosine, Lamivudine and Efavirenz Versus Zidovudine, Lamivudine and Efavirenz in the Starting Treatment of HIV","status":"COMPLETED","sponsor":"Clinical Trial Agency of HIV Study Group","startDate":"2004-06","conditions":"HIV Infections","enrollment":360},{"nctId":"NCT00080522","phase":"NA","title":"Strategies for Delivering Anti-HIV Therapy in South Africa","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2005-02","conditions":"HIV Infections","enrollment":813},{"nctId":"NCT00127972","phase":"PHASE4","title":"2NN & CHARM Long-Term Follow-up Study","status":"COMPLETED","sponsor":"International Antiviral Therapy Evaluation Center","startDate":"2004-02","conditions":"HIV Infections","enrollment":763},{"nctId":"NCT00075231","phase":"PHASE2","title":"A Simplified Kaletra® (Lopinavir/Ritonavir)-Based Therapy Versus a Sustiva® (Efavirenz)-Based Standard of Care in Previously Non-Treated HIV-Infected Subjects","status":"COMPLETED","sponsor":"Abbott","startDate":"2003-12","conditions":"HIV Infections","enrollment":150},{"nctId":"NCT00162643","phase":"PHASE4","title":"PI Vs. NNRTI Based Therapy for HIV Advanced Disease","status":"UNKNOWN","sponsor":"Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran","startDate":"2004-12","conditions":"Acquired Immunodeficiency Syndrome","enrollment":300},{"nctId":"NCT00002410","phase":"PHASE3","title":"A Study of Three Different Anti-HIV Drug Combinations in HIV-Infected Patients","status":"COMPLETED","sponsor":"Dupont Merck","startDate":"","conditions":"HIV Infections","enrollment":""},{"nctId":"NCT00005000","phase":"PHASE4","title":"Treatment With Nelfinavir or Efavirenz of HIV-Infected Patients Who Have Never Received Anti-HIV Drugs","status":"UNKNOWN","sponsor":"Agouron Pharmaceuticals","startDate":"1999-12","conditions":"HIV Infections","enrollment":200},{"nctId":"NCT00005018","phase":"PHASE4","title":"Safety and Effectiveness of a Combination Anti-HIV Drug Treatment","status":"COMPLETED","sponsor":"Glaxo Wellcome","startDate":"1999-07","conditions":"HIV Infections","enrollment":150},{"nctId":"NCT00004852","phase":"PHASE2","title":"Safety and Effectiveness of Lamivudine When Given Once a Day Versus Twice a Day in Combination With Other Anti-HIV Drugs in HIV-Infected Adults Who Have Never Received Anti-HIV Drugs","status":"COMPLETED","sponsor":"Glaxo Wellcome","startDate":"1999-09","conditions":"HIV Infections","enrollment":""},{"nctId":"NCT00011895","phase":"PHASE4","title":"Safety and Effectiveness of TRIZIVIR (Abacavir/Lamivudine/Zidovudine) With Efavirenz in HIV-Infected Patients Who Have Never Taken Anti-HIV Drugs","status":"UNKNOWN","sponsor":"GlaxoSmithKline","startDate":"2001-02","conditions":"HIV Infections","enrollment":400},{"nctId":"NCT00004585","phase":"PHASE4","title":"A Study of the Safety and Effectiveness of Combination Anti-HIV Therapy in HIV-Infected Adults","status":"COMPLETED","sponsor":"Glaxo Wellcome","startDate":"1999-10","conditions":"HIV Infections","enrollment":40}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"zidovudine + lamivudine + efavirenz","genericName":"zidovudine + lamivudine + efavirenz","companyName":"Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran","companyId":"instituto-nacional-de-ciencias-medicas-y-nutricion-salvador-zubiran","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination of three antiretroviral drugs inhibits HIV replication by blocking reverse transcriptase and integrase enzymes, preventing the virus from copying its genetic material and integrating into host cells. Used for HIV-1 infection in treatment-naïve and treatment-experienced patients.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}